An Open-Label, Phase I, Dose-Escalation Study Evaluating The Safety And Tolerability Of Gdc-0853 In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia
Latest Information Update: 23 Jun 2022
At a glance
- Drugs Fenebrutinib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Genentech
- 16 Jun 2022 Status changed from active, no longer recruiting to completed.
- 17 Jun 2020 Planned End Date changed from 27 Feb 2023 to 28 Feb 2023.
- 03 Jun 2020 Planned End Date changed from 27 Feb 2021 to 27 Feb 2023.